On December 15, 2025, the U.S. FDA approved Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Addyi was previously approved ...
I frequently hear complaints of decreased libido in perimenopausal and menopausal women on hormone replacement therapy, even after they have tried estrogen and progesterone replacement or testosterone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results